Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Chemotherapy and Rituximab for Aggressive B-NHL in Children and Adolescents
NCT07168980Phase 3Recruiting
- Sponsor
- Children's Oncology Group
- Start
- Jul 2025
- Primary completion
- Jun 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in mature B-cell non-Hodgkin lymphoma, sponsored by Children's Oncology Group. Started Jul 2025; status: recruiting.
02
Drugs
rituximab
03
Conditions
mature B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07168980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07168980.